Literature DB >> 1424102

Effects of the subcutaneous administration of enkephalins on tail-flick response and righting reflex of developing rats.

T Oka1, X F Liu, T Kajita, N Ohgiya, K Ghoda, T Taniguchi, Y Arai, T Matsumiya.   

Abstract

The s.c. administration of [Met5]-enkephalin to 10-day-old rats pretreated with the mixture of 3 peptidase inhibitors, amastatin, captopril and phosphoramidon, produced the inhibition of tail-flick response and loss of righting reflex. When infant rats were pretreated with the mixture of any combination of two peptidase inhibitors, however, the change in both the response and the reflex were not produced at all by enkephalin injection, indicating that 3 kinds of enzymes, amastatin-sensitive aminopeptidase(s), captopril-sensitive peptidyl dipeptidase A and phosphoramidon-sensitive endopeptidase 24.11, played an important role in the inactivation of enkephalin after its systemic administration. Additionally, the fact that the two enkephalin-induced effects were more effectively antagonized by naloxone, a relatively selective mu-opioid antagonist, than by naltrindole, a specific delta-antagonist, or by nor-binaltorphimine, a specific kappa-antagonist, showed that these two effects were produced by the interaction of enkephalin with mu receptors. Moreover the involvement of mu receptors in the production of these two effects was shown by the fact that the s.c. administration of [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin, a selective mu agonist, also produced these two effects which were more effectively antagonized by naloxone than by naltrindole or nor-binaltorphimine. Since the magnitude of the two effects induced by enkephalins in 15-day-old rats was significantly lower than that in 10-day-old rats, and the two enkephalin-induced effects were not produced at all in 20-day-old rats, a maturation-induced decrease in the permeability of the blood-brain barrier against opioid peptides was indicated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424102     DOI: 10.1016/0165-3806(92)90167-u

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  5 in total

1.  P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.

Authors:  Sarah M Brown; Scott D Campbell; Amanda Crafford; Karen J Regina; Michael J Holtzman; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2012-06-27       Impact factor: 4.030

2.  Potentiation of [Met5]enkephalin-induced antinociception by mixture of three peptidase inhibitors in rat.

Authors:  Tomohiko Murata; Masanobu Yoshikawa; Mariko Watanabe; Shigeru Takahashi; Mitsuru Kawaguchi; Hiroyuki Kobayashi; Toshiyasu Suzuki
Journal:  J Anesth       Date:  2014-04-05       Impact factor: 2.078

3.  Electrophysiological studies on the postnatal development of the spinal antinociceptive effects of the delta opioid receptor agonist DPDPE in the rat.

Authors:  W Rahman; A H Dickenson
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 4.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

5.  A method to estimate the potency of the mu-component of an opioid having mixed mu-, and kappa- and/or delta-agonist activities.

Authors:  X F Liu; X T Fan; K Kitamura; T Taniguchi; T Oka
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.